Table 2.

Factors associated with underprescription of oral anticoagulants

Characteristics	Model1 [OR(95%CI)] N = 3165	Model2 [OR(95%CI)] N = 3165	Model3 [OR(95%CI)] N = 3165
Age(years),80–84	Ref	-	-
Age(years),85–89	1.48(1.25,1.74)	-	-
Age(years),90 +	2.66(2.09,3.42)	-	-
Sex, Female	0.67(0.57,0.78)	-	-
Clinical department, Cardiology	Ref	Ref	-
Clinical department, Geriatrics	2.97(2.45,3.61)	2.2(1.78,2.71)	-
Clinical department, Neurology	1.25(0.96,1.63)	1.21(0.92,1.57)	-
Clinical department, Others	4.23(3.43,5.24)	4.2(3.39,5.21)	-
Year, 2016–2017	Ref	Ref	-
Year, 2017–2018	0.66(0.52,0.83)	0.65(0.51,0.83)	-
Year, 2018–2019	0.48(0.38,0.6)	0.47(0.37,0.6)	-
Year, 2019–2020	0.34(0.27,0.42)	0.32(0.25,0.4)	-
CHA2DS2-VASC Score	0.92(0.87,0.98)	0.94(0.88,1)	1(0.93,1.07)
HAS- BLED Score < 3	Ref	Ref	Ref
3 <  = HAS- BLED Score <  = 4	0.93(0.71,1.19)	0.86(0.66,1.11)	1.11(0.84,1.46)
HAS- BLED Score >  = 5	1.31(1,1.72)	1.08(0.82,1.43)	1.89(1.38,2.57)
Prescription of antiplatelets, Y	1.69(1.45,1.97)	1.57(1.35,1.84)	2.21(1.85,2.63)
Clopidogrel, Y	1.77(1.49,2.09)	1.59(1.34,1.89)	2.1(1.75,2.54)
CCI, 0	Ref	Ref	Ref
CCI 1–2	1.2(0.99,1.44)	1.08(0.89,1.3)	1(0.82,1.23)
CCI 3 +	2.02(1.62,2.53)	1.68(1.34,2.11)	1.39(1.09,1.78)
Dementia, Y	2.16(1.6,2.96)	1.68(1.24,2.33)	1.48(1.07,2.07)
Thromboembolic disease, Y	1.12(0.86,1.47)	1.14(0.88,1.5)	0.74(0.56,1)
Stroke, Y	0.92(0.78,1.07)	0.83(0.71,0.98)	0.89(0.74,1.08)
Hypertension, Y	0.97(0.83,1.14)	0.96(0.81,1.13)	0.98(0.82,1.16)
Diabetes, Y	0.93(0.79,1.1)	0.91(0.77,1.08)	0.97(0.82,1.17)
CHD, Y	0.96(0.83,1.12)	0.87(0.74,1.01)	1.01(0.86,1.19)

Model 1: Univariate logistic regression analysis between no anticoagulation and characteristic variables

Model 2: Multivariate logistic regression analysis between no anticoagulation and characteristic variables adjusted by age and sex

Model 3: Multivariate logistic regression analysis between no anticoagulation and characteristic variables adjusted by age, sex, clinical department and year